News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Clinical Data, Inc. Reports Second Quarter Fiscal Year 2011 Operational and Financial Results


11/9/2010 10:50:58 AM

NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA) today announced operational and financial results for the second quarter ended September 30, 2010. The Company confirmed that its commercial preparations for the launch of vilazodone, if approved for the treatment of depression, are accelerating as the decision date assigned under the Prescription Drug User Fee Act (PDUFA) of January 22, 2011 rapidly approaches. Phase III development of Stedivaze, the Company’s coronary vasodilator for use in nuclear-SPECT myocardial perfusion imaging, is also advancing with plans to initiate a second Phase III trial in early calendar year 2011.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES